Quest is committed to develop & commercialize oncology product candidates for cancer treatment by combining immunotherapeutic antibodies with chemotherapy, photodynamic therapy or immunoadjuvants. One candidate, Oregovomab, an anti-CA 125 antibody, is in use in combination with front-line chemotherapy to treat advanced ovarian cancer in a Phase IIb clinical trial in 13 centers in Italy and the U.S. Quest is also developing products for cancer & dermatology based on its SonoLight Technology. (Bio AB)